[The involvement of D-1 and D-2 dopamine receptors in the effects of neuroleptics and the pathogenesis of schizophrenia].
The authors presents the literature concerned with the role of D-1 and D-2 dopamine receptors in the pathogenesis of schizophrenia and the effects of neuroleptics. The author concludes that substances which stimulate the D-1 receptors may decrease symptoms of schizophrenia and restrain the formation of tardive dyskinesia, whilst blocking the D-1 receptors may act anti-psychotically without causing tardive dyskinesia. However, they cannot be used with people because of their considerable toxicity. The introduction of new generation of neuroleptics.
Wielgosz
M
M
Zakładu Farmakologii Akademii Medycznej, Lublinie.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009434:Neural Pathways / Q000187:drug effects; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*
D014150:Antipsychotic Agents; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2
Rola receptorów dopaminergicznych D-1 i D-2 w działaniu neuroleptyków i patogenezie schizofrenii.